TRAIL induces endocytosis of its death receptors in MDA-MB-231 breast cancer cells

Cancer Biology and Therapy

Volumn 8, Issue 10, 2009, Pages 917-922

  Zhang, Yaqin ^a   Yoshida, Tatsushi ^a   Zhang, Baolin ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Apoptosis; Breast cancer cells; Caspases; Cleavage; Death receptor; Endocytosis; TNF related apoptosis inducing ligand (TRAIL)

Indexed keywords

CASPASE; DEATH RECEPTOR; DEATH RECEPTOR 4; DEATH RECEPTOR 5; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; XEDAR RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER THERAPY; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; ENDOCYTOSIS; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; ENDOCYTOSIS; FEMALE; GREEN FLUORESCENT PROTEINS; HUMANS; KINETICS; PHYCOERYTHRIN; PLASMIDS; RECEPTORS, DEATH DOMAIN; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECOMBINANT FUSION PROTEINS; TEMPERATURE; TIME FACTORS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFECTION;

EID: 68049125070     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.10.8141     Document Type: Article

References (26)

1. Finnberg N, El Deiry WS. TRAIL death receptors as tumor suppressors and drug targets. Cell Cycle 2008; 7:1525-8.
2. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003; 10:66-75.
3. Daniel D, Wilson NS. Tumor necrosis factor: renaissance as a cancer therapeutic? Curr Cancer Drug Targets 2008; 8:124-31.
4. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104:155-62.
5. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001; 7:383-5.
6. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008; 8:782-98.
7. Tollefson AE, Hermiston TW, Lichtenstein DL, Colle CF, Tripp RA, Dimitrov T, et al. Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells. Nature 1998; 392:726-30.
8. Lee KH, Feig C, Tchikov V, Schickel R, Hallas C, Schütze S, et al. The role of receptor internalization in CD95 signaling. EMBO J 2006; 25:1009-23.
9. Schneider-Brachert W, Tchikov V, Neumeyer J, Jakob M, Winoto-Morbach S, Held-Feindt J, et al. Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles. Immunity 2004; 21:415-28.
10. Austin CD, Lawrence DA, Peden AA, Varfolomeev EE, Totpal K, De Mazière AM, et al. Death-receptor activation halts clathrin-dependent endocytosis. Proc Natl Acad Sci USA 2006; 103:10283-8.
11. Kohlhaas SL, Craxton A, Sun XM, Pinkoski MJ, Cohen GM. Receptor-mediated endocytosis is not required for TRAIL-induced apoptosis. J Biol Chem 2007; 282:12831-41.
12. Zhang Y, Zhang B. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Mol Cancer Res 2008; 6:1861-71.
13. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 1999; 59:734-41.
14. Rahman M, Davis SR, Pumphrey JG, Bao J, Nau MM, Meltzer PS, et al. TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res Treat 2009; 113:217-30.
15. Singh TR, Shankar S, Chen X, Asim M, Srivastava RK, et al. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res 2003; 63:5390-400.
16. Chinnaiyan AM, Prasad U, Shankar S, Hamstra DA, Shanaiah M, Chenevert TL, et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci USA 2000; 97:1754-9.
17. Okuyama M, Laman H, Kingsbury SR, Visintin C, Leo E, Eward KL, et al. Small-molecule mimics of an alpha-helix for efficient transport of proteins into cells. Nat Methods 2007; 4:153-9.
18. Sun X, Yau VK, Briggs BJ, Whittaker GR. Role of clathrin-mediated endocytosis during vesicular stomatitis virus entry into host cells. Virology 2005; 338:53-60.
19. Rejman J, Bragonzi A, Conese M. Role of clathrin- and caveolae-mediated endocytosis in gene transfer mediated by lipo- and polyplexes. Mol Ther 2005; 12:468-74.
20. van der Luit AH, Vink SR, Klarenbeek JB, Perrissoud D, Solary E, Verheij M, et al. A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells. Mol Cancer Ther 2007; 6:2337-45.
21. Tollefson AE, Toth K, Doronin K, Kuppuswamy M, Doronina OA, Lichtenstein DL, et al. Inhibition of TRAIL-induced apoptosis and forced internalization of TRAIL receptor 1 by adenovirus proteins. J Virol 2001; 75:8875-87.
22. Ren YG, Wagner KW, Knee DA, Aza-Blanc P, Nasoff M, Deveraux QL. Differential regulation of the TRAIL death receptors DR4 and DR5 by the signal recognition particle. Mol Biol Cell 2004; 15:5064-74.
23. Yoshida T, Shiraishi T, Horinaka M, Wakada M, Sakai T. Glycosylation modulates TRAIL-R1/death receptor 4 protein: different regulations of two pro-apoptotic receptors for TRAIL by tunicamycin. Oncol Rep 2007; 18:1239-42.
24. Jin Z, McDonald ER III, Dicker DT, El-Deiry WS. Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J Biol Chem 2004; 279:35829-39.
25. Ceresa BP, Schmid SL. Regulation of signal transduction by endocytosis. Curr Opin Cell Biol 2000; 12:204-10.
26. Zhang B, Zhang Y, Dagher MC, Shacter E. Rho GDP dissociation inhibitor protects cancer cells against drug-induced apoptosis. Cancer Res 2005; 65:6054-62.